NxStage Medical, Inc. (NASDAQ:NXTM) – Stock analysts at Leerink Swann dropped their FY2017 EPS estimates for NxStage Medical in a research report issued on Wednesday. Leerink Swann analyst D. Antalffy now forecasts that the medical device company will post earnings per share of ($0.05) for the year, down from their previous estimate of ($0.02). Leerink Swann currently has a “Market Perform” rating and a $30.00 price target on the stock.

NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.03). The business had revenue of $92.20 million during the quarter, compared to the consensus estimate of $96.47 million. NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.03) earnings per share.

ILLEGAL ACTIVITY NOTICE: “FY2017 EPS Estimates for NxStage Medical, Inc. Reduced by Analyst (NXTM)” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/08/fy2017-eps-estimates-for-nxstage-medical-inc-reduced-by-analyst-nxtm.html.

A number of other brokerages also recently commented on NXTM. William Blair downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a research note on Monday, August 7th. Jefferies Group LLC downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating and cut their target price for the company from $33.00 to $30.00 in a research note on Tuesday, August 8th. Stephens downgraded shares of NxStage Medical from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $33.00 to $30.00 in a research note on Wednesday, August 9th. Zacks Investment Research raised shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Thursday, August 10th. Finally, BTIG Research downgraded shares of NxStage Medical from a “buy” rating to a “neutral” rating in a research note on Friday, August 11th. One equities research analyst has rated the stock with a sell rating and nine have issued a hold rating to the company’s stock. NxStage Medical has an average rating of “Hold” and an average target price of $30.25.

NxStage Medical (NXTM) opened at 27.90 on Friday. The firm has a 50 day moving average of $26.92 and a 200 day moving average of $25.94. The firm’s market cap is $1.84 billion. NxStage Medical has a 1-year low of $20.45 and a 1-year high of $30.80.

A number of institutional investors have recently added to or reduced their stakes in NXTM. Teachers Advisors LLC increased its stake in NxStage Medical by 3.8% during the 4th quarter. Teachers Advisors LLC now owns 116,182 shares of the medical device company’s stock worth $3,045,000 after buying an additional 4,257 shares during the period. Nationwide Fund Advisors increased its stake in NxStage Medical by 551.0% during the 1st quarter. Nationwide Fund Advisors now owns 258,975 shares of the medical device company’s stock worth $6,948,000 after buying an additional 219,196 shares during the period. Russell Investments Group Ltd. increased its stake in NxStage Medical by 67.9% during the 1st quarter. Russell Investments Group Ltd. now owns 28,847 shares of the medical device company’s stock worth $773,000 after buying an additional 11,668 shares during the period. Bank of New York Mellon Corp increased its stake in NxStage Medical by 0.5% during the 1st quarter. Bank of New York Mellon Corp now owns 639,866 shares of the medical device company’s stock worth $17,168,000 after buying an additional 2,914 shares during the period. Finally, UBS Asset Management Americas Inc. increased its stake in NxStage Medical by 148.4% during the 1st quarter. UBS Asset Management Americas Inc. now owns 32,532 shares of the medical device company’s stock worth $873,000 after buying an additional 19,434 shares during the period. 93.20% of the stock is currently owned by hedge funds and other institutional investors.

In related news, SVP Winifred L. Swan sold 3,500 shares of NxStage Medical stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $23.14, for a total transaction of $80,990.00. Following the sale, the senior vice president now owns 17,270 shares of the company’s stock, valued at approximately $399,627.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Matthew W. Towse sold 4,300 shares of NxStage Medical stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $23.29, for a total transaction of $100,147.00. Following the sale, the senior vice president now directly owns 29,637 shares in the company, valued at approximately $690,245.73. The disclosure for this sale can be found here. Insiders have sold a total of 54,900 shares of company stock worth $1,491,266 in the last ninety days. 4.70% of the stock is currently owned by insiders.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Earnings History and Estimates for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.